Phase I Study of GX15-070 (NSC 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma.

Trial Profile

Phase I Study of GX15-070 (NSC 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 May 2013

At a glance

  • Drugs Obatoclax (Primary) ; Bortezomib
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 02 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Nov 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
    • 14 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top